Literature DB >> 17443309

Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death.

J Schrader1, W Rennekamp, U Niebergall, M Schoppet, H Jahr, M D Brendel, D Hörsch, L C Hofbauer.   

Abstract

AIMS/HYPOTHESIS: Pro-inflammatory cytokines play a crucial role in immune-mediated beta cell destruction, an essential mechanism in the pathogenesis of type 1 diabetes mellitus. Microarray analysis recently identified osteoprotegerin (OPG; now known as tumour necrosis factor receptor superfamily, member 11b [TNFRSF11B]) as a cytokine-induced gene in beta cells. The aim of the present study was to characterise the functional role and signalling pathways of OPG that are involved in cytokine-induced beta cell death.
MATERIALS AND METHODS: As cellular models, the rat beta cell line INS-1E and human primary pancreatic islets were employed. The effects of IL-1beta and TNF-alpha on OPG expression were characterised by northern blot and immunoassay. The effect of OPG on beta cell survival was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Signalling pathways were evaluated by western blot analysis using antibodies against p38 mitogen-activated protein kinases (MAPK), c-Jun N-terminal kinase and extracellular signal-regulated kinase 1/2.
RESULTS: The INS-1E cell line and primary pancreatic islets expressed OPG mRNA and secreted OPG protein, both of which were enhanced by IL-1beta and TNF-alpha. Exposure to IL-1beta resulted in sustained phosphorylation of p38 MAPK in INS-1E cells and subsequent cell death. Administration of exogenous OPG prevented both IL-1beta-induced beta cell death and sustained p38 MAPK phosphorylation. CONCLUSIONS/
INTERPRETATION: Our data indicate that cytokine-induced production of OPG may protect beta cells from further damage. This protective effect is, at least in part, mediated through inhibition of p38 MAPK phosphorylation. Thus OPG is an autocrine or paracrine survival factor for beta cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443309     DOI: 10.1007/s00125-007-0672-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  11 in total

Review 1.  Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

Authors:  Y Y Kong; W J Boyle; J M Penninger
Journal:  Immunol Today       Date:  2000-10

Review 2.  Islet transplantation as a treatment for diabetes - a work in progress.

Authors:  R Paul Robertson
Journal:  N Engl J Med       Date:  2004-02-12       Impact factor: 91.245

3.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

Authors:  L Huang; J Xu; D J Wood; M H Zheng
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction.

Authors:  D Ou; D L Metzger; X Wang; J Huang; P Pozzilli; A J Tingle
Journal:  Diabetologia       Date:  2002-10-23       Impact factor: 10.122

5.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

Authors:  J G Emery; P McDonnell; M B Burke; K C Deen; S Lyn; C Silverman; E Dul; E R Appelbaum; C Eichman; R DiPrinzio; R A Dodds; I E James; M Rosenberg; J C Lee; P R Young
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

6.  Role of p38 mitogen-activated protein kinase (p38 MAPK) in cytokine-induced rat islet cell apoptosis.

Authors:  J Saldeen; J C Lee; N Welsh
Journal:  Biochem Pharmacol       Date:  2001-06-15       Impact factor: 5.858

Review 7.  A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis.

Authors:  D L Eizirik; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2001-12       Impact factor: 10.122

8.  International trial of the Edmonton protocol for islet transplantation.

Authors:  A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

9.  Identification of novel cytokine-induced genes in pancreatic beta-cells by high-density oligonucleotide arrays.

Authors:  A K Cardozo; M Kruhøffer; R Leeman; T Orntoft; D L Eizirik
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

10.  Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Authors:  Therese Standal; Carina Seidel; Øyvind Hjertner; Torben Plesner; Ralph D Sanderson; Anders Waage; Magne Borset; Anders Sundan
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

View more
  12 in total

1.  The transcriptional response of the islet to pregnancy in mice.

Authors:  Sebastian Rieck; Peter White; Jonathan Schug; Alan J Fox; Olga Smirnova; Nan Gao; Rana K Gupta; Zhao V Wang; Philipp E Scherer; Mark P Keller; Alan D Attie; Klaus H Kaestner
Journal:  Mol Endocrinol       Date:  2009-07-02

2.  Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway.

Authors:  Nagesha Guthalu Kondegowda; Rafael Fenutria; Ilana R Pollack; Michael Orthofer; Adolfo Garcia-Ocaña; Josef M Penninger; Rupangi C Vasavada
Journal:  Cell Metab       Date:  2015-06-18       Impact factor: 27.287

Review 3.  How, When, and Where Do Human β-Cells Regenerate?

Authors:  Giorgio Basile; Rohit N Kulkarni; Noel G Morgan
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

Review 4.  Novel factors modulating human β-cell proliferation.

Authors:  J Shirakawa; R N Kulkarni
Journal:  Diabetes Obes Metab       Date:  2016-09       Impact factor: 6.577

5.  Mesenteric lymph duct drainage attenuates acute lung injury in rats with severe intraperitoneal infection.

Authors:  Yanmin Zhang; Shukun Zhang; Naiqiang Tsui
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

6.  ERK5 plays an essential role in gestational beta-cell proliferation.

Authors:  Congde Chen; Suichun Wu; Xiaokun Lin; Dazhou Wu; Shane Fischbach; Xiangwei Xiao
Journal:  Cell Prolif       Date:  2017-11-21       Impact factor: 6.831

7.  Prolactin receptors and placental lactogen drive male mouse pancreatic islets to pregnancy-related mRNA changes.

Authors:  Lotte Goyvaerts; Katleen Lemaire; Ingrid Arijs; Julien Auffret; Mikaela Granvik; Leentje Van Lommel; Nadine Binart; Peter in't Veld; Frans Schuit; Anica Schraenen
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

8.  Osteoprotegerin Regulates Pancreatic β-Cell Homeostasis upon Microbial Invasion.

Authors:  Yukiko Kuroda; Kenta Maruyama; Hideki Fujii; Isamu Sugawara; Shigeru B H Ko; Hisataka Yasuda; Hidenori Matsui; Koichi Matsuo
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

9.  Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice.

Authors:  Xiao-Wen Chen; Xiao-Yan Du; Yu-Xian Wang; Jian-Cheng Wang; Wen-Ting Liu; Wen-Jing Chen; Hong-Yu Li; Fen-Fen Peng; Zhao-Zhong Xu; Hong-Xin Niu; Hai-Bo Long
Journal:  Mediators Inflamm       Date:  2016-01-06       Impact factor: 4.711

10.  Common Variants in CLDN2 and MORC4 Genes Confer Disease Susceptibility in Patients with Chronic Pancreatitis.

Authors:  Anil K Giri; Shallu Midha; Priyanka Banerjee; Ankita Agrawal; Syed Jafar Mehdi; Rajan Dhingra; Ismeet Kaur; Ramesh Kumar G; Ritika Lakhotia; Saurabh Ghosh; Kshaunish Das; Samir Mohindra; Surinder Rana; Deepak K Bhasin; Pramod K Garg; Dwaipayan Bharadwaj
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.